Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1/eIF4E/c-MYC Signaling

Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia

(2023) Siyu Gu et al.   Experimental Hematology & Oncology

Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia

(2022) Kristína Šimoničová et al.   DRUG RESISTANCE UPDATES

High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study

(2022) Jun Li et al.   Blood Cancer Journal

High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabine in newly diagnosed patients with AML: A single arm, phase 2 trial

(2022) Jun Li et al.   Frontiers in Oncology

Targeting NAT10 Induces Apoptosis Associated With Enhancing Endoplasmic Reticulum Stress in Acute Myeloid Leukemia Cells

(2021) Jie Zi et al.   Frontiers in Oncology

Phospho-eIF4E: a new target for acute myeloid leukemia

(2021) Xiao feng Jia et al.   CURRENT PROTEIN & PEPTIDE SCIENCE

A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients

(2021) María P. Martínez Sánchez et al.   ANNALS OF HEMATOLOGY

MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies

(2021) Seyed Esmaeil Ahmadi et al.   Journal of Hematology & Oncology

A 2:1 randomized, open-label, phase II study of selinexor vs. physician’s choice in older patients with relapsed or refractory acute myeloid leukemia

(2021) Kendra Sweet et al.   LEUKEMIA & LYMPHOMA

Pan-cancer analysis reveals the roles of XPO1 in predicting prognosis and tumorigenesis

(2021) Lei Zhao et al.   Translational Cancer Research

Inhibition of XPO-1 Mediated Nuclear Export through the Michael-Acceptor Character of Chalcones

(2021) Marta Gargantilla et al.   Pharmaceuticals

IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?

(2020) Michael Leisch et al.   BRITISH JOURNAL OF HAEMATOLOGY

Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience

(2020) Armon Azizi et al.   LEUKEMIA & LYMPHOMA

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

(2020) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-κB repressing factor

(2019) Xin-Jie Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Azacitidine resistance caused by LAMP2 deficiency: a therapeutic window for the use of autophagy inhibitors in MDS/AML patients?

(2019) Guillaume Robert et al.   Autophagy

Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study

(2019) Bhavana Bhatnagar et al.   LEUKEMIA & LYMPHOMA

Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia

(2019) Ramzi Abboud et al.   HAEMATOLOGICA

Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma

(2018) Ujjawal H. Gandhi et al.   Clinical Lymphoma Myeloma & Leukemia

Azacitidine Use for Myeloid Neoplasms

(2018) Riad El Fakih et al.   Clinical Lymphoma Myeloma & Leukemia

MYC protein expression is an important prognostic factor in acute myeloid leukemia

(2018) Maro Ohanian et al.   LEUKEMIA & LYMPHOMA

Acute myeloid leukemia: 2019 update on risk-stratification and management

(2018) Elihu H. Estey   AMERICAN JOURNAL OF HEMATOLOGY

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

(2018) Courtney D. DiNardo et al.   BLOOD

Therapeutic Inhibition of Myc in Cancer. Structural Bases and Computer-Aided Drug Discovery Approaches

(2018) Lavinia Carabet et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Venetoclax with decitabine or azacitidine for AML

(2018) Manjulika Das   LANCET ONCOLOGY

Selective Inhibitors of Nuclear Export (SINE) compounds block proliferation and migration of triple negative breast cancer cells by restoring expression of ARRDC3

(2017) Young Hwa Soung et al.   Oncotarget

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies

(2016) Changchun Deng et al.   BLOOD

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

MYC-mediated Synthetic Lethality for Treatment of Hematological Malignancies

(2015) Xin Li et al.   CURRENT CANCER DRUG TARGETS

Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice

(2015) J Etchin et al.   LEUKEMIA

Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer

(2015) Janet Mendonca et al.   Oncotarget

BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD

(2014) W. Fiskus et al.   MOLECULAR CANCER THERAPEUTICS

Prognostic impact and targeting of CRM1 in acute myeloid leukemia

(2013) K. Kojima et al.   BLOOD

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

(2013) S. H. Petersdorf et al.   BLOOD

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

(2012) R. Lapalombella et al.   BLOOD

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia

(2012) P. Ranganathan et al.   BLOOD

MYC oncogene in myeloid neoplasias

(2012) M. Dolores Delgado et al.   Clinical & Translational Oncology

Selective Inhibitors of Nuclear Export Block Pancreatic Cancer Cell Proliferation and Reduce Tumor Growth in Mice

(2012) Asfar S. Azmi et al.   GASTROENTEROLOGY

Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells

(2012) J Etchin et al.   LEUKEMIA

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

(2010) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL

(2009) W. Ci et al.   BLOOD

Anthracycline Dose Intensification in Acute Myeloid Leukemia

(2009) Hugo F. Fernandez et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse

(2008) H. Kroeger et al.   BLOOD

Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group

(2008) Thomas Büchner et al.   JOURNAL OF CLINICAL ONCOLOGY